New hope for Tough-to-Treat blood cancer
NCT ID NCT06965114
Summary
This study is testing a new two-drug combination (tovorafenib + rituximab) for hairy cell leukemia that has come back or hasn't responded to prior treatment. It will also compare this new combo to the current standard treatment (cladribine + rituximab) for patients who haven't started any treatment yet. The goal is to see if the new combination is safe and more effective at getting rid of cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.